The burden, prevention and control status, and prospects of global lung cancer

doi:10.19983/j.issn.2096-8493.20250048

Abstract

Abstract:

Lung cancer is the most common cancer worldwide and the leading cause of cancer-related deaths. Despite certain progresses made in areas such as early screening, targeted therapy and immunotherapy in recent years, lung cancer remains a major global public health challenge. This article describes the burden and prevalence of lung cancer globally and in China, analyzes the disparities in lung cancer burden across regions with varying Human Development Index, and discusses the current status and prospects of lung cancer prevention and treatment.

Key words: Lung neoplasms, Disease burden, Healthy people programs, Public health, Universal precautions

CLC Number:

R734.2

Wang Ning, Wang Baohua. The burden, prevention and control status, and prospects of global lung cancer[J]. Journal of Tuberculosis and Lung Disease , 2025, 6(3): 256-260. doi: 10.19983/j.issn.2096-8493.20250048

References 31

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263. doi:10.3322/caac.21834.
[2]	曹梦迪, 陈万青. GLOBOCAN 2022全球癌症统计数据解读. 中国医学前沿杂志(电子版, 2024, 16(6): 1-5. doi:10.12037/YXQY.2024.06-01.
[3]	王宝华. 中国恶性肿瘤及危险因素流行病学调查回顾与展望. 环境卫生学杂志, 2024, 14(10): 793-801. doi:10.13421/j.cnki.hjwsxzz.2024.10.001.
[4]	张希, 杨雷, 刘硕, 等. 2022年全球恶性肿瘤统计报告解读. 中华肿瘤杂志, 2024, 46(7): 710-721. doi:10.3760/cma.j.cn112152-20240416-00152.
[5]	Wéber A, Morgan E, Vignat J, et al. Lung cancer mortality in the wake of the changing smoking epidemic: a descriptive study of the global burden in 2020 and 2040. BMJ Open, 2023, 13(5): e065303. doi:10.1136/bmjopen-2022-065303.
[6]	Xia C, Zheng R, Zeng H, et al. Provincial-level cancer burden attributable to active and second-hand smoking in China. Tob Control, 2019, 28(6): 669-675. doi:10.1136/tobaccocontrol-2018-054583. pmid: 30322976
[7]	Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol, 2023, 20(9): 624-639. doi:10.1038/s41571-023-00798-3. pmid: 37479810
[8]	Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, et al. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol, 2014, 15(5): 489-538. doi:10.1016/S1470-2045(14)70029-4. pmid: 24731404
[9]	Guan WJ, Zheng XY, Chung KF, et al. Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action. Lancet, 2016, 388(10054): 1939-1951. doi:10.1016/S0140-6736(16)31597-5.
[10]	Rajappa S, Singh M, Uehara R, et al. Cancer incidence and mortality trends in Asia based on regions and human development index levels: an analyses from GLOBOCAN 2020. Curr Med Res Opin, 2023, 39(8): 1127-1137. doi:10.1080/03007995.2023.2231761.
[11]	郭祯, 王伟, 王红, 等. 2022年全球肺癌终生罹患风险和死亡风险分析. 中国肿瘤, 2025, 34(2): 81-88. doi:10.11735/j.issn.1004-0242.2025.02.A001.
[12]	Zhang M, Yang L, Wang L, et al. Trends in smoking prevalence in urban and rural China, 2007 to 2018: Findings from 5 consecutive nationally representative cross-sectional surveys. PLoS Med, 2022, 19(8): e1004064. doi:10.1371/journal.pmed.1004064.
[13]	Bruce N, Dherani M, Liu R, et al. Does household use of biomass fuel cause lung cancer? A systematic review and evaluation of the evidence for the GBD 2010 study. Thorax, 2015, 70(5): 433-441. doi:10.1136/thoraxjnl-2014-206625. pmid: 25758120
[14]	Zheng R, Zhang S, Wang S, et al. Lung cancer incidence and mortality in China: Updated statistics and an overview of temporal trends from 2000 to 2016. J Natl Cancer Cent, 2022, 2(3):139-147. doi:10.1016/j.jncc.2022.07.004.
[15]	莫淼, 王泽洲, 郑莹, 等. 2022年全球及中国乳腺癌流行病学特征分析. 海军军医大学学报, 2025, 46 (4): 497-503. doi:10.16781/j.CN31-2187/R.20240649.
[16]	李小钰, 黄青, 吴雨濛, 等. 2022年全球癌症统计报告的窄谱总结和展望. 肿瘤防治研究, 2024, 51(5):307-312. doi:10.3971/j.issn.1000-8578.2024.24.0437.
[17]	Hsu YC, Cheng SY, Chien MN, et al. Impact of social and economic factors on global thyroid cancer incidence and mortality. Eur Arch Otorhinolaryngol, 2023, 280(9): 4185-4193. doi:10.1007/s00405-023-07992-0.
[18]	韩冰峰, 郑荣寿, 孙可欣, 等. 人类发展指数对女性恶性肿瘤发病和死亡的影响研究. 中国肿瘤, 2023, 32(6): 436-444. doi:10.11735/j.issn.1004-0242.2023.06.A006.
[19]	张正, 张莉芳, 刘彦廷, 等. 《2022全球癌症统计报告》解读. 中国医院统计, 2024, 31(5): 393-400. doi:10.3969/j.issn.1006-5253.2024.05.014.
[20]	National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365(5): 395-409. doi:10.1056/NEJMoa1102873.
[21]	Field JK, Vulkan D, Davies MPA, et al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Eur, 2021, 10:100179. doi:10.1016/j.lanepe.2021.100179.
[22]	刘潇衍, 王孟昭. 非小细胞肺癌靶向治疗年度进展2024. 国际呼吸杂志, 2025, 45(1): 26-34. doi:10.3760/cma.j.cn131368-20241125-00720.
[23]	马骏, 张红颖, 吴艾平, 等. 免疫检查点抑制剂在肺癌治疗中的研究进展. 国际肿瘤学杂志, 2021, 48(11): 683-687. doi:10.3760/cma.j.cn371439-20201231-00135.
[24]	中国医师协会肿瘤多学科诊疗专业委员会, 国家肿瘤质控中心肺癌质控专家委员会. 肺癌免疫检查点抑制剂联合放疗中国专家共识(2025版). 中华肿瘤杂志, 2025, 47(1): 39-64. doi:10.3760/cma.j.cn112152-20240929-00422.
[25]	蔡林, 朱称心, 张兴龙, 等. 全球肺癌流行数据解读. 中华流行病学杂志, 2024, 45(4): 585-590. doi:10.3760/cma.j.cn112338-20230920-00172.
[26]	赵美荣, 王玉红. 我国城市癌症早诊早治项目研究现状. 护理研究, 2023, 37(10): 1765-1771. doi:10.12102/j.issn.1009-6493.2023.10.014.
[27]	中国共产党中央委员会, 中华人民共和国国务院. 中共中央国务院印发《“健康中国2030”规划纲要》. 2016-10-25.
[28]	健康中国行动推进委员会. 健康中国行动 (2019—2030). 2019-07-09.
[29]	赫捷, 李霓, 陈万青, 等. 中国肺癌筛查与早诊早治指南(2021,北京). 中国综合临床, 2021, 37(3): 193-207. doi:10.3760/cma.j.cn112152-20210119-00060.
[30]	李亚运, 钱东福, 周守君, 等. 某地区肺癌住院患者直接经济负担城乡差异比较研究. 重庆医学, 2016, 45(5): 661-663. doi:10.3969/j.issn.1671-8348.2016.05.027.
[31]	田梦媛, 崔丹, 张欲晓, 等. 3种抗肿瘤靶向药物的可负担性评价——以湖北省为例. 中国药房, 2017, 28(20): 2746-2749. doi:10.6039/j.issn.1001-0408.2017.20.03.